Literature DB >> 27751619

Rate of tympanic membrane perforation after intratympanic steroid injection.

Michael C Topf1, David W Hsu2, Douglas R Adams3, Tingting Zhan4, Stanley Pelosi2, Thomas O Willcox2, Brian McGettigan2, Kyle W Fisher2.   

Abstract

PURPOSE: To determine the rate of persistent tympanic membrane perforation after intratympanic steroid injection. To determine which comorbid conditions and risk factors are associated with prolonged time to perforation closure following intratympanic steroid injection.
MATERIALS AND METHODS: Clinical data were gathered for patients who had undergone intratympanic steroid injection to treat sudden sensorineural hearing loss or Ménière's disease. Primary outcomes analysis included rate of persistent tympanic membrane perforation, defined as perforation at least 90days following last injection, and time to perforation healing. Age, sex, number of injections, smoking status, diabetes mellitus, previous head and neck irradiation, and concurrent oral steroids, were analyzed as potential predictors of persistent perforation.
RESULTS: One hundred ninety two patients were included in this study. Three patients (1.6%) had persistent tympanic membrane perforations. All three patients received multiple injections. One patient underwent tympanoplasty for repair of persistent perforation. The median time to perforation healing was 18days. There was no statistically significant variable associated with time to perforation healing. However, patients with prior history of head and neck radiation averaged 36.5days for perforation healing compared to 17.5days with no prior history of radiation and this approached statistical significance (p=0.078).
CONCLUSIONS: The rate of persistent tympanic membrane perforation following intratympanic steroid injection is low. Patients with a history of radiation to the head and neck may be at increased risk for prolonged time for closure of perforation.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27751619     DOI: 10.1016/j.amjoto.2016.09.004

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


  8 in total

Review 1. 

Authors:  Vincent Wu; Edward A Sykes; Michael M Beyea; Matthew T W Simpson; Jason A Beyea
Journal:  Can Fam Physician       Date:  2019-07       Impact factor: 3.275

2.  Ultrasound-induced microbubble cavitation via a transcanal or transcranial approach facilitates inner ear drug delivery.

Authors:  Ai-Ho Liao; Chih-Hung Wang; Ping-Yu Weng; Yi-Chun Lin; Hao Wang; Hang-Kang Chen; Hao-Li Liu; Ho-Chiao Chuang; Cheng-Ping Shih
Journal:  JCI Insight       Date:  2020-02-13

Review 3.  Approach to Ménière disease management.

Authors:  Vincent Wu; Edward A Sykes; Michael M Beyea; Matthew T W Simpson; Jason A Beyea
Journal:  Can Fam Physician       Date:  2019-07       Impact factor: 3.275

4.  Quality of life after intratympanic steroid injection for Ménière's disease.

Authors:  Annejet A Schenck; Claire C Bommeljé; Peter Paul G van Benthem; Henk M Blom
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-05-17

5.  Intratympanic (IT) Therapies for Menière's Disease: Some Consensus Among the Confusion.

Authors:  Desi P Schoo; Grace X Tan; Matthew R Ehrenburg; Seth E Pross; Bryan K Ward; John P Carey
Journal:  Curr Otorhinolaryngol Rep       Date:  2017-05-03

6.  Safety of Repeated-Dose Intratympanic Injections with AM-101 in Acute Inner Ear Tinnitus.

Authors:  Hinrich Staecker; Michael Morelock; Timothy Kramer; Pavel Chrbolka; Joong Ho Ahn; Thomas Meyer
Journal:  Otolaryngol Head Neck Surg       Date:  2017-06-13       Impact factor: 3.497

7.  Adjuvant Migraine Medications in the Treatment of Sudden Sensorineural Hearing Loss.

Authors:  Mehdi Abouzari; Khodayar Goshtasbi; Janice T Chua; Donald Tan; Brooke Sarna; Tina Saber; Harrison W Lin; Hamid R Djalilian
Journal:  Laryngoscope       Date:  2020-04-03       Impact factor: 3.325

Review 8.  Effects of intratympanic gentamicin and intratympanic glucocorticoids in Ménière's disease: a network meta-analysis.

Authors:  Weiming Hao; Huiqian Yu; Huawei Li
Journal:  J Neurol       Date:  2021-01-02       Impact factor: 4.849

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.